Clinical Trial Results:
A 24-week international, randomized, parallel-group, double-blind, placebo-controlled Phase III study with a 24-week extension period to evaluate the efficacy and safety of dapagliflozin therapy when added to the therapy of patients with type 2 diabetes with inadequate glycaemic control on insulin.
Summary
|
|
EudraCT number |
2007-007540-10 |
Trial protocol |
FI HU ES AT SK DE BG NL GB |
Global completion date |
01 Jan 2011
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
01 Oct 2016
|
First version publication date |
01 Oct 2016
|
Other versions |
|
Summary report(s) |
D1690C00006-full data set |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.